Bayer CEO rebuked over Monsanto acquisition
Majority of shareholders vote against absolving Werner Baumann and other managers of responsibility for their actions in the $63bn takeover in 2018
Munich/Berlin/Frankfurt — As the Bayer management digs in against a growing shareholder rebellion over the acquisition of Monsanto, attention will shift from the German company’s headquarters back to US courts.
That is where the German pharma and chemicals giant faces 13,400 lawsuits claiming that Monsanto’s Roundup weedkiller causes cancer. Even as it fights the cases, the company’s shareholders handed CEO Werner Baumann an unprecedented rebuke last week.
Bayer rose 2.3% to €60.12 in early Frankfurt trading. Including the impact of Bayer’s dividend payment, which took effect on Monday, the stock fell 2.2%. Here’s where things stand.
At a fractious, 13-hour gathering in Bonn on Friday, more than 55% of shareholders voted against absolving Baumann and other managers of responsibility for their actions in the $63bn takeover in 2018.
Bayer’s board circled the wagons afterward, saying it maintains full confidence in Baumann. Several top investors consider the move a sign that Bayer is unwilling to address shareholder concerns, according to people familiar with the situation.
Will Baumann have to go?
The vote was non-binding, but other German CEOs have lost their jobs even after securing more support than Baumann. Several large investors said however that they prefer the chief to remain in place because a change to Bayer’s management board could further delay a resolution to the US litigation and any strategic review.
What are shareholders seeking?
Investors want Bayer to consider an overhaul of the board, take a more forthcoming approach in dealing with the US litigation and conduct a sweeping review — including a potential breakup of the conglomerate into crop science and pharmaceutical companies, said the people familiar with the situation, who asked not to be identified because the deliberations are private. A Bayer representative declined to comment on investors’ call for changes.
What happens next?
The management’s fate may ultimately lie in the hands of US courts, where Bayer has already lost two Roundup cases and lawsuits are proliferating through multiple channels. In one set of proceedings, a US federal judge ordered Bayer in April to pursue mediation, asking the company to try to settle legal challenges that have wiped more than €35bn off the market value.
Separately, a state court in California is hearing a case brought by a couple in their 70s who both have cancer. The jury is expected to rule as soon as May.
Bayer denies that Roundup causes cancer and the company has been holding out hope for a court win that would give Baumann some breathing space as the company hones its legal response to the swelling wave of litigation.
A third loss, however, could force the company to accelerate talks on a global settlement, which analysts have said could top $5bn.